As with the prior assessments, subjects were asked to report for testing in the morning following 12 hr without food and to not participate in heavy exercise during the 24 hr period before testing
To assess the associations of semaglutide with incident AUD (first time diagnosis of AUD), the study population included 83,825 patients who had active medical encounters for the diagnosis of obesity in 6/202112/2022, were for the first time (new-user design) prescribed semaglutide or non-GLP-1RA anti-obesity medications (naltrexone, topiramate, bupropion, orlistat, phentermine) 54 during 6/202112/2022 (time zero or index event), had no diagnosis of AUD on or before the index event and had a diagnosis of at least one of obesity-associated comorbidities (T2D, hypertension, hypercholesterolemia, hyperlipidemia, heart diseases, stroke) on or before the index event
Am I clear on the subscription timing, renewal dates, and what is and isn't refundable once prescribing begins
Understanding your dosing in practical terms matters
Semaglutide can help regulate blood sugar, promote steady weight loss, reduce appetite, and improve certain metabolic health markers
These effects are often linked to the bodys immune response or allergic reactions to the medication or its components
